Fenfluramine

This is an old revision of this page, as edited by Cacycle (talk | contribs) at 03:41, 29 March 2007 (mv to Category:Serotonin receptor agonists …using wikEd). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fenfluramine is a drug that was part of the Fen-Phen anti-obesity medication (the other drug being phentermine). Also known as Pondimin, fenfluramine was introduced on the U.S. market in 1973. It is the racemic form of dexfenfluramine. It is designed to increase the level of the neurotransmitter serotonin. This depresses the central nervous system, regulating mood and appetite. The end result is a feeling of fullness and loss of appetite.

Fenfluramine
Clinical data
Pregnancy
category
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Unscheduled, Withdrawn from market
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life20 hours
ExcretionRenal
Identifiers
  • N-ethyl-1-[3-(trifluoromethyl)-
    phenyl]propan-2-amine
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.006.616 Edit this at Wikidata
Chemical and physical data
FormulaC12H16F3N
Molar mass231.257 g·mol−1

The drug was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis.

The distinctive valvular abnormality seen with fenfluramine is a thickening of the leaflet and chordae tendinae. Roth (2007) suggested a mechanism by which fenfluramine damaged the valves. Heart valves also have serotonin receptors, which regulate their growth. He reported that fenfluramine and its active metabolite norfenfluramine stimulated the serotonin receptors 5-hydroxytryptamine (5-HT). In particular norfenfluramine is a potent agonist (stimulant) of 5-HT2B receptors. These receptors are plentiful in human cardiac valves and appear to be essential for normal cardiac development. Roth suggested that the mechanism by which fenfluramine causes damage is through inappropriately stimulating the valve cells to divide. This valve damage is found in other drugs that act on 5-HT2B receptors.

References

  • Roth, B Drugs and Valvular Heart Disease. N Engl J Med 2007;356:6 PMID 17202450